The Complete Guide to Current and Emerging Weight Loss Peptide Medications
Comprehensive review of current and emerging weight loss medications covers GLP-1 drugs, dual/triple agonists, amylin analogs, and emerging oral formulations for obesity treatment.
Quick Facts
What This Study Found
The obesity drug pipeline has expanded from single GLP-1 agonists to dual/triple agonists and amylin combinations, with oral formulations emerging for improved access.
Key Numbers
Drugs covered: Liraglutide, Semaglutide, Setmelanotide, Tirzepatide (injectable); Phentermine, Phentermine/Topiramate, Bupropion/Naltrexone, Orlistat, Metformin (oral); Cagrilintide, Bimagrumab (emerging).
How They Did This
Narrative review of current and emerging parenteral and oral weight loss medications, covering mechanisms, efficacy, safety, and clinical positioning.
Why This Research Matters
With multiple new obesity drugs approaching approval, patients and clinicians need a comprehensive guide to compare all available and upcoming options.
The Bigger Picture
We are entering an era where obesity will be treated with the same pharmacological sophistication as hypertension or diabetes — multiple drug classes, combination therapies, and individualized selection based on patient profiles.
What This Study Doesn't Tell Us
Rapidly evolving field — some drugs are still in clinical trials. Head-to-head comparisons are limited. Long-term data for newer agents is sparse.
Questions This Raises
- ?Which weight loss drug will ultimately win the market?
- ?Will oral GLP-1 formulations achieve the same efficacy as injections?
- ?How should clinicians choose between the many available options?
Trust & Context
- Key Stat:
- From 15% to 24% weight loss Weight loss medications have progressed from single GLP-1 agonists (15%) to triple agonists (24%) in just a few years
- Evidence Grade:
- Moderate evidence: narrative review covering drugs at various stages from approved to investigational.
- Study Age:
- Published in 2025. Most comprehensive review of the current and emerging obesity drug pipeline.
- Original Title:
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.
- Published In:
- Diseases (Basel, Switzerland), 13(5) (2025)
- Authors:
- Al Lawati, Abdullah, Alhabsi, Ayman, Rahul, Rhieya, Savino, Maria-Luisa, Alwahaibi, Hamed, Das, Srijit, Al Lawati, Hanan
- Database ID:
- RPEP-09817
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What weight loss drugs are available now?
Currently approved: semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound). Coming soon: retatrutide (triple agonist), CagriSema (semaglutide + amylin), higher-dose oral semaglutide, survodutide, and others.
Will there be a weight loss pill instead of injection?
Oral semaglutide (Rybelsus) already exists for diabetes, and higher oral doses are being tested for weight loss. Multiple oral GLP-1 formulations are in development. Within a few years, effective oral weight loss peptide drugs should be available.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09817APA
Al Lawati, Abdullah; Alhabsi, Ayman; Rahul, Rhieya; Savino, Maria-Luisa; Alwahaibi, Hamed; Das, Srijit; Al Lawati, Hanan. (2025). Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.. Diseases (Basel, Switzerland), 13(5). https://doi.org/10.3390/diseases13050129
MLA
Al Lawati, Abdullah, et al. "Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.." Diseases (Basel, 2025. https://doi.org/10.3390/diseases13050129
RethinkPeptides
RethinkPeptides Research Database. "Current and Emerging Parenteral and Peroral Medications for ..." RPEP-09817. Retrieved from https://rethinkpeptides.com/research/al-2025-current-and-emerging-parenteral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.